Lazard Starts Verenium (VRNM) at Buy
More News related to VRNM
- Verenium (VRNM) Announces Departure of CFO
- Verenium Announces Organizational Changes
- SectorWatch.biz Issues MarketStats on MVTG, PX, DD, VRNM, AVR and PEIX
- Verenium (VRNM) Reports Q3 Loss of $2.02
- Verenium Reports Financial Results for the Third Quarter 2008
More News related to New Coverage
- Canaccord Initiates Coverage on Ituran (ITRN) with a Buy, Sees Significant Upside From Defensible Business Model and Brazilian Opportunity
- Merriman Curhan Starts Regal Entertainment (RGC) at Buy
- Stifel Nicolaus Starts Penn National Gaming (PENN) at Buy
- Stanford Starts Energy Recovery (ERII) at Buy
- Lazard Starts Marvell (MRVL) at Hold
Lazard Capital initiates coverage on Verenium (Nasdaq: VRNM) with a Buy rating.
Verenium Corporation engages in the development and production of specialty enzyme products, and production and commercialization of biofuels.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
